PowerVision (Belmont, CA) a development-stage medical device company focusing on an accommodating intraocular lens to allow for dynamic near and far focus adjustments, closed a $13.2M Series C financing, bringing the total round to $37.2M. Participants include Johnson & Johnson Development Corp., Venrock, Advanced Technology Ventures and Frazier Healthcare Ventures.

Catabasis Pharmaceuticals (Cambridge, MA) a clinical-stage biopharmaceutical company focused on fatty acid conjugated compounds for severe hypertriglyceridemia, diabetes, inflammatory and metabolic diseases, closed a $8M Series A financing bringing total round to $47.6M. Participants include SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

Acceleron Pharma (Cambridge, MA) is a clinical-stage biopharmaceutical company focused on protein therapeutics for anemia, cancer, Duchenne Muscular Dystrophy and bone loss diseases, closed a $30.4M Series D financing. Participants have included Advanced Technology Ventures, Avalon Ventures, Bessemer Venture Partners, Celgene, Flagship Ventures, MPM Capital, Orbimed, Polaris Ventures, QVT Financial, Sutter Hill Ventures and Venrock.

Verastem (Boston, MA) a development stage biopharmaceutical company focused on the treatment of cancer by targeting stem cells, closed a $32M Series B financing. Participants include Advanced Technology Ventures, Astellas Venture Management, Longwood Founders Fund, Bessemer Venture Partners, Cardinal Partners and MPM Capital. Thanx for your patience as we catch-up.

Second Genome (San Francisco, CA) a commercial-stage microbial profiling company designed to enable diagnostic/prognostic signatures and target identification, closed a $5M Series A financing. Participants include Advanced Technology Ventures, Morgenthaler Ventures, Wavepoint Ventures and Seraph Group. Thanx for your patience as we catch-up.

Valeritas (Bridgewater, NJ) a commercial-stage developer of a disposable insulin delivery device, closed a $150M Series C financing. Participants include Welsh, Carson, Anderson & Stowe, MPM Capital, Pitango Venture Capital, Abingworth Management, Advanced Technology Ventures, Onset Ventures, HLM Venture Partners, Agate Medical Investments, CHL Medical Partners and Kaiser Permanente Ventures.

EndoGastric Solutions (Redmond, WA) a commercial-stage medical device company focused on endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI disorders, closed a $30M Series F financing. Participants have included Canaan Partners, Radius Ventures, Advanced Technology Ventures, Chicago Growth Partners, DeNovo Ventures, Foundation Medical Partners, MPM Capitaland [...]

Calithera Biosciences (San Francisco, CA) a preclinical-stage small molecule company focused on caspase activators for oncologic applications, closed a $40M Series A financing. Participants include Morgenthaler Ventures, U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital.

Zeltiq (Pleasanton, CA) a commercial-stage medical device company focused on lipolysis for fat reduction and other dermatological applications, closed a $25M Series D financing. Participants include Aisling Capital, Venrock, Frazier Healthcare Ventures and Advanced Technology Ventures.

Coskata (Warrenville, IL) a development-stage bacterial fermentation biofuels company closed a $23.7M Series D financing. Participants include Total, Blackstone Group, Advanced Technology Ventures, Globespan Capital Partners, General Motors, GreatPoint Ventures and Khosla Ventures.

Altura Medical (San Clemente, CA) a development-stage medical device company focused on the treatment of abdominal aortic aneurysms, closed a $20M Series A financing. Participants include New Leaf Venture Partners, Advanced Technology Ventures and SV Life Sciences.

Catabasis Pharmaceuticals (Cambridge, MA) a preclinical-stage company focused on lipid mediators for the treatment of inflammatory and metabolic diseases, closed a $39.6M Series A financing. Participants include SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.

EndoGastric Solutions (Redmond, WA) a commercial-stage medical device company focused on endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI disorders, closed a $21.5M Series E financing. Participants have included Advanced Technology Ventures, Chicago Growth Partners, DeNovo Ventures, Foundation Medical Partners, MPM Capitaland Oakwood Medical Investors. Note: [...]